DDX53 and neoplasm: We treated either shScram-treated or shCCL5-treated CT26 allografts with the Arf1 inhibitors and found that DU102 could robustly suppress tumor growth of the shScram-treated CT26 allografts but not the shCCL5-treated CT26 allografts (Fig. 2i and j, Supplementary Fig. S2f).